AMGN Amgen Inc
Company Analysis
Latest News
Amgen’s Tavneos Faces EU Ban, Citing Misleading Clinical Data
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for Amgen’s...
Amgen Upgraded to Buy, Boosted by Obesity and Eye-Disease Drug Trials
Wall Street Zen upgraded Amgen Inc. (NASDAQ:AMGN) from hold to buy on June 14, 2026. The stock maintains a consensus hold rating with an average price target...
Amgen's first quarter 2026 revenue grew 6% as strong performance from key growth products offset biosimilar pressures.
Amgen reported first quarter 2026 revenues of $8.6 billion, a 6% year-over-year increase, and non-GAAP EPS of $5.15, up 5% from the prior year. The results...
Amgen Inc Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Amgen is expected to report Q1 2026 revenue of $8.67 billion and adjusted EPS of $4.75, with its current $344.55 share price trading roughly 3.4% below the...
OpenAI Launches GPT-Rosalind with Moderna and Amgen, Targeting Faster Drug Discovery
OpenAI launched GPT-Rosalind, a new series of AI models engineered to accelerate life sciences research. The tool assists scientists in synthesizing evidence,...